

Global clinical development pipeline

Updated: 25 Feb 2026

Phase 1		Phase 2		Phase 3		Accepted submissions Major markets (U.S., CN, EU, JP)					
Sonrotoclax ● 101 B-cell malignancies ● 102 B-cell malignancies ● 103 AML/MDS ● 105 R/R MM t(11;14) ● 108 Dose ramp-up	BCL2i	BGB-58067 ● 101 Lung and Solid tumors	MTA Coop. PRMT5i	Xaluritamig⁴ ● 20180146 mCRPC	STEAPI x CD3 XmAb[®]	Sonrotoclax ● 203 R/R WM ● 204 TN CLL/SLL	BCL2i	Zanubrutinib ● 306 TN MCL ● 308 R/R MZL, R/R FL ● 309 pMN	BTKi	Sonrotoclax ● 201 R/R MCL (U.S., EU)	BCL2i
BGB-16673 ● 101 B-cell malignancies ● 102 B-cell malignancies ● 104 B-cell malignancies ● 107 Chronic spontaneous urticaria	BTK CDAC	BG-89894³ ● 101 Lung and Solid tumors	MAT2Ai	BG-C0979 ● 101 Solid tumors**	ADAM9 ADC	BGB-16673 ● 101 R/R CLL and R/R WM ● 102 R/R CLL	BTK CDAC	Sonrotoclax ● 301 TN CLL ● 302 R/R MCL ● 303 R/R CLL/SLL ● 304 TN CLL (vs. AV)	BCL2i	Tarlatamab⁴ ● 20230273 3L+ SCLC (CN) ● 20210004 2L SCLC (CN)	DLL3 x CD3 BiTE[®]
BG-71332 ● 101 Relative bioavailability	BTKi + BCL2i	BG-60366 ● 101 Lung cancers	EGFR CDAC	BGB-45035 ● 101 Immunology and Inflammation	IRAK4 CDAC	Blinatumomab⁴ ● 20180257 R/R B-ALL SubQ, MRD+	CD19 x CD3 BiTE[®]	Tarlatamab⁴ ● 20240092 2L SCLC (Alt dosing)	DLL3 x CD3 BiTE[®]	Tislelizumab ● 305 IL GC (JP) ● Alternate dosing Q6W (CN)	PD-1 mAb
BGB-21447 ● 102 HR+ Breast cancer	BCL2i	BG-T187 ● 101 Lung and GI Cancers	EGFR x MET x MET tsAb	BG-A3004 ● 101 Immunology and Inflammation**	KLRG1 mAb	Tarlatamab⁴ ● 20240092 2L SCLC (Alt dosing)	DLL3 x CD3 BiTE[®]	BGB-16673 ● 302 R/R CLL ● 303 R/R CLL/SLL ● 304 R/R CLL/SLL (vs. Pirto)	BTK CDAC	Tarlatamab⁴ ● 20200041 1L ES-SCLC MTx ● 20240178 1L ES-SCLC Ind. and MTx ● 20230016 LS-SCLC	DLL3 x CD3 BiTE[®]
BGB-43395 ● 101/102 BC and solid tumors	CDK4i	BG-C0902 ● 101 Lung and GI cancers	EGFR x MET x MET tsADC			BGB-45035 ● 201 Rheumatoid Arthritis	IRAK4 CDAC	Tarlatamab⁴ ● 20200041 1L ES-SCLC MTx ● 20240178 1L ES-SCLC Ind. and MTx ● 20230016 LS-SCLC	BTK CDAC	Zanidatamab⁵ ● 301 1L HER2+ GEA	HER2 bsAb
BG-C9074¹ ● 101 BC and solid tumors	B7-H4 ADC	BG-53038 ● 101 Lung and GI cancers	Pan-KRAsi					Tarlatamab⁴ ● 20200041 1L ES-SCLC MTx ● 20240178 1L ES-SCLC Ind. and MTx ● 20230016 LS-SCLC	BTK CDAC	Tislelizumab ● 310 1L UBC ● 316 SubQ	PD-1 mAb
BG-C9074¹ ● 101 BC and solid tumors	B7-H4 ADC	BG-C477 ● 101 Lung and GI cancers	CEA ADC					Tarlatamab⁴ ● 20200041 1L ES-SCLC MTx ● 20240178 1L ES-SCLC Ind. and MTx ● 20230016 LS-SCLC	BTK CDAC	Tislelizumab ● 310 1L UBC ● 316 SubQ	PD-1 mAb
BG-68501² ● 101 BC and solid tumors	CDK2i	BG-C137 ● 101 GI cancers	FGFR2b ADC					Tarlatamab⁴ ● 20200041 1L ES-SCLC MTx ● 20240178 1L ES-SCLC Ind. and MTx ● 20230016 LS-SCLC	BTK CDAC	Tislelizumab ● 310 1L UBC ● 316 SubQ	PD-1 mAb
BGB-B455 ● 101 Gyn. and solid tumors	CLDN 6 x CD3 bsAb	BG-B2033 ● 101 Solid tumors	GPC3 x 4-1BB bsAb					Tarlatamab⁴ ● 20200041 1L ES-SCLC MTx ● 20240178 1L ES-SCLC Ind. and MTx ● 20230016 LS-SCLC	BTK CDAC	Tislelizumab ● 310 1L UBC ● 316 SubQ	PD-1 mAb
BG-75202 ● 101 BC and solid tumors	KAT6A/Bi	BG-26808 ● 101 Solid tumors/pan-tumor	HPK1i					Tarlatamab⁴ ● 20200041 1L ES-SCLC MTx ● 20240178 1L ES-SCLC Ind. and MTx ● 20230016 LS-SCLC	BTK CDAC	Tislelizumab ● 310 1L UBC ● 316 SubQ	PD-1 mAb
BG-75098 ● 101 BC and solid tumors	CDK2 CDAC							Tarlatamab⁴ ● 20200041 1L ES-SCLC MTx ● 20240178 1L ES-SCLC Ind. and MTx ● 20230016 LS-SCLC	BTK CDAC	Tislelizumab ● 310 1L UBC ● 316 SubQ	PD-1 mAb

- Hematology
- Lung
- Breast / Gynecological
- Gastrointestinal
- Other cancers
- Immunology and Inflammation

¹ DualityBio collaboration, ² Ensem collaboration, ³ CSPC collaboration, ⁴ Amgen collaboration, ⁵ Zymeworks/Jazz collaboration
 Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details
 ** Trial is listed on clinicaltrials.gov, but may not have subjects enrolled